Galectin Therapeutics Inc. (FRA:PHPN)

Market Cap	318.12M
Revenue (ttm)	n/a
Net Income (ttm)	-31.91M
Shares Out	n/a
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	4.840
Previous Close	4.700
Day's Range	4.840 - 4.840
52-Week Range	0.815 - 5.800
Beta	n/a
RSI	55.01
Earnings Date	Nov 21, 2025

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PHPN

Financial Performance

Financial numbers in USD